Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo

NCT00594568 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00594568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00594568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2008
Completion date
May 31, 2011
Enrollment
1,537 (actual)
Sites
148

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease